| Date | Title | Description |
| 25.08.2026 | Bridge to Life Secures $110 Million for Organ Transplant Innovation. VitaSmart Drives Commercial Surge. | Bridge to Life secured $110 million in Series C equity and debt financing. This significant capital influx will accelerate the nationwide commercialization of VitaSmart, its FDA-cleared hypothermic oxygenated perfusion system for liver tran... |
| 14.08.2026 | Soticlestat Revived: Perceptive Advisors Bets FDA Rejected Trial Design, Not Drug Itself | By Benjamin Eddie
Published: Aug 14 2026, 4:49 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 13.08.2026 | Bridge to Life Raises $110 Million in Series C |
DULUTH, GA, Bridge to Life, a market leader in organ preservation solutions and perfusion technologies, announced the successful completion of a $110 million Series C and debt financing.
>> Click here for more funding data on Bridge ... |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
Tue, Aug 11, 2026 13:00 CET Report this content
EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing |
Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |
| 19.05.2026 | Quince Therapeutics: $187 Million Private Placement And Orphai Acquisition To Advance Pulmonary Disease Pipeline | Quince Therapeutics announced the acquisition of Orphai Therapeutics along with a private placement financing valued at up to $187 million to expand its pulmonary disease pipeline. The acquisition adds Orphai’s lead program, LAM-001, an inh... |
| 08.01.2026 | Significant Advances in Pharmaceutical Pipelines for Underserved Diseases |
Oculis Holding AG has announced that its drug candidate Privosegtor was granted breakthrough therapy designation by the FDA for the treatment of optic neuritis (ON), a rare neuro‑ophthalmic condition. This approval expedites the review of ... |
| 07.09.2025 | Galvanize Therapeutics Secures $100M: Revolutionizing Oncology and Chronic Lung Disease Treatment | Galvanize Therapeutics landed a significant $100 million Series C financing. This substantial capital propels its innovative pulsed electric field (PEF) therapies. The Redwood City firm targets critical unmet needs in oncology and chronic l... |
| 06.09.2025 | Galvanize Therapeutics: $100 Million Raised For Advancing Therapies For Cancer And Chronic Lung Disease | Galvanize Therapeutics, a commercial-stage medical technology company developing novel pulsed electric field therapies, has announced the successful close of a $100 million Series C financing round. The round was oversubscribed, reflecting ... |
| 03.09.2025 | Mercy BioAnalytics Raises $59M in Series B Funding | Mercy BioAnalytics, a Waltham, MA-based company which specializes in extracellular vesicle-based liquid biopsies for the early detection of cancer, raised $59M in Series B funding.
The round was led by Novalis and Sozo Ventures, with partic... |
| 18.06.2024 | Telepsychiatry Practice Talkiatry Secures $130M to Expand Value-Based Mental Healthcare Model | What You Should Know:
– Talkiatry, a leading provider of high-quality, in-network psychiatric care raises $130M led by Andreessen Horowitz (a16z) with participation from Perceptive Advisors and debt financing from Banc of California.
– Talk... |
| 11.06.2024 | Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth | Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform
NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody, the leading national... |
| 14.05.2024 | Revenue growth and $50m debt financing for SOPHiA GENETICS |
With currently 463 core genomics customers, SOPHiA GENETICS continues to see strong adoption of its SOPHiA DDM platform in clinical markets globally. In the first quarter, SOPHiA GENETICS announced partnerships with several prominent healt... |
| 03.04.2024 | Addex spin-off launched with USD63 million investment |
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Today the company announced that it will contribute a portfolio of... |
| 13.03.2024 | IVF uncertainty aside, startups rush to offer fertility care amid rising demand | AI tools, egg freezing, surrogacy, IUI, donorship, oncofertility, genetic analysis, loans, and more
In the aftermath of the Roe v. Wade overturn, U.S. fertility clinics (and patients alongside them) are battling an unlikely complication in ... |
| 27.02.2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term
When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| 20.02.2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| 15.02.2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know:
– Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| 03.08.2022 | MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities | - Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland
- $75 million at closing strengthens balance sheet and extends runway to fourth quarter of 2024
LONDON and NEW YORK, ... |
| 24.02.2022 | Omada Health Raises $192M to Expand Digital Therapeutics for Chronic Disease | What You Should Know:
– Omada Health, a chronic care integrated healthcare provider, today announced its $192M in Series E funding round led by Fidelity Management & Research Company with participation from aMoon, existing investors Per... |
| 20.01.2022 | Investors disagree on whether digital health is in a bubble after another record funding haul in 2021 | If there were any doubts that digital health funding, especially in the U.S., is on a rocket ride straight to the stratosphere, they were removed with the latest funding report from CBInsights. Are we in a bubble? Is there irrational exuber... |
| 15.11.2021 | Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II | Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutations
Initial data from both Phase 2 clinical trials... |
| 15.11.2021 | Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II | Funds will be used to further advance lasofoxifene through late-stage clinical development as a next-generation oral SERM to treat women with increasingly prevalent ESR1 breast cancer mutations
Initial data from both Phase 2 clinical trials... |
| 13.05.2021 | Cue Health Raises $235M to Scale Connected, Molecular Diagnostic System | What You Should Know:
– Cue Health Inc., a health technology company, today announced the closing of a $235 million private financing round. The investment includes participation from new investors Perceptive Advisors, MSD Capital, and Koch... |
| 13.05.2021 | Perceptive Advisors Closes $515M Early-Stage Biotech Fund | What You Should Know:
– Perceptive Advisors and biotech accelerator Xontogeny, focused on seed investment, incubation and collaboration, have raised their second venture capital fund, the Perceptive Xontogeny Ventures Fund II (PXV Fund II),... |
| 12.05.2021 | Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies | – Five new drug therapeutic companies supported with strategic and operational guidance and seed capital –
– Programs include a diverse portfolio of therapeutic modalities across a wide range of disease areas –
BOSTON–(BUSINESS WIRE)–May 12... |
| 12.05.2021 | Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP | – PXV Fund II plans to lead Series A financings in 10 to 12 early-stage life sciences companies –
– PXV Funds total $725 million of AUMs since launching strategy less than 18 months ago –
NEW YORK & BOSTON–(BUSINESS WIRE)–May 12, 2021–
... |
| 12.05.2021 | Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP | Join Transform 2021 this July 12-16. Register for the AI event of the year.
– PXV Fund II plans to lead Series A financings in 10 to 12 early-stage life sciences companies –
– PXV Funds total $725 million of AUMs since launching strategy le... |
| 12.05.2021 | Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies | Join Transform 2021 this July 12-16. Register for the AI event of the year.
– Five new drug therapeutic companies supported with strategic and operational guidance and seed capital –
– Programs include a diverse portfolio of therapeutic mod... |
| 12.05.2021 | Juno Diagnostics Announces Closing of $25 Million Series A Financing Led by Perceptive Xontogeny Venture Fund | Join Transform 2021 this July 12-16. Register for the AI event of the year.
– Reproductive health pioneers developing genetic testing solutions to dramatically improve access to prenatal care for all women in all geographies –
– Experienced... |
| 12.05.2021 | Juno Diagnostics Announces Closing of $25 Million Series A Financing Led by Perceptive Xontogeny Venture Fund | – Reproductive health pioneers developing genetic testing solutions to dramatically improve access to prenatal care for all women in all geographies –
– Experienced leadership team developed and launched the industry’s first noninvasive pre... |
| 12.05.2021 | Perceptive Advisors Closes Fund II, at $515M | Perceptive Advisors, a NYC-based investment management firm focused on the life sciences sector, closed Perceptive Xontogeny Venture Fund II, LP, at $515m, to further its early-stage life sciences platform.
PXV Fund II includes existing inv... |
| 01.03.2021 | Agile Therapeutics, Inc. announced that it has received $45 million in funding from Perceptive Advisors LLC | On March 1, 2021, the company amended the terms of the transaction. The company now raised $45 million in the transaction. The investor provided additional $10 million in its fourth tranche close. |
| 08.02.2021 | Ally Bridge Portfolio News – Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III | Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT”
Nautilus Bio... |
| 12.01.2021 | Earli : Raises $40 Million Series A Funding Led by Khosla Ventures, With Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital | The biotech industry has been aspiring to develop breakthrough technologies that hold promise for acting early on cancer when the chances of survival are much higher. Bioengineering firm, Earli, which developed in stealth a new platform tec... |
| 07.01.2021 | IsoPlexis Announces $135 Million Series D Led by Perceptive Advisors | IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with par... |
| 07.01.2021 | IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors | |
| 10.12.2019 | Perceptive Advisors Closes Inaugural Fund, at $210M | Perceptive Advisors, a New York, NY-based investment management firm focused in life sciences, closed its inaugural venture capital fund, the Perceptive Xontogeny Venture Fund, LP, at $210m.
Commitments came from a global investor base incl... |
| 10.12.2019 | Perceptive Advisors raises $210M for its Inaugural Fund to invest in early-stage biotech startups | Perceptive Advisors, an investment management firm focused in life sciences, has closed $210 for its inaugural venture capital fund, the Perceptive Xontogeny Venture Fund, LP (the “PXV Fund”), solely focused on investment in early-stage lif... |
| 10.12.2019 | Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups | – New fund plans to lead Series A financings in 8 to 10 companies –
– Fund will favor companies seeded at the Xontogeny accelerator, which allows operational and development efficiency to entrepreneur-led startups –
NEW YORK & BOSTON–(B... |
| 10.12.2019 | Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups | – New fund plans to lead Series A financings in 8 to 10 companies –
– Fund will favor companies seeded at the Xontogeny accelerator, which allows operational and development efficiency to entrepreneur-led startups –
NEW YORK & BOSTON–(B... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, today announced the completion of an oversubscribed $79.5 million Series B financing.
Cowe... |
| 21.08.2019 | Oncorus Raises $79.5M Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oncorus, Inc., an oncolytic virus company focused on driving innovation to transform outcomes for cancer patients, today announced the completion of an oversubscribed $79.5 million Series B financing.
Cowe... |
| 21.08.2019 | Oncorus Announces $79.5 Million Series B Financing Co-Led by Cowen Healthcare Investments and Perceptive Advisors | –Company advancing broad pipeline of next-generation oncolytic virus therapies for both intratumoral and intravenous administration for multiple solid tumor indications–
–Novel innovations to enhance potency and safety enable best-in-class ... |
| 27.06.2019 | PanTheryx Raises $50 Million From Perceptive Advisors | BOULDER, Colo.--(BUSINESS WIRE)--PanTheryx, a biotechnology company focused on addressing serious GI related health conditions, announced today that it has completed $50 million in new financing with Perceptive Advisors. Proceeds from the f... |
| 26.06.2019 | Boulder biotech company PanTheryx gets $50 million | Boulder biotechnology company PanTheryx is getting $50 million from Perceptive Advisors to develop treatments for a variety of gut-related medical conditions and to promote its medical foods, the company announced today.
PanTheryx leverages... |
| 07.01.2018 | Vitruvias Therapeutics Completes $11.5M Series A Led by JW Asset Management and Perceptive Advisors | AUBURN, Ala.--(BUSINESS WIRE)--Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led... |
| 07.01.2018 | Vitruvias Therapeutics Completes $11.5M Series A Led by JW Asset Management and Perceptive Advisors | AUBURN, Ala.--(BUSINESS WIRE)--Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led... |
| 21.09.2017 | Landos Biopharma Raises $10M Series A Led by Perceptive Advisors | Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced today it has raised $10 million in a Series A financing led by life sciences investment management fi... |
| 13.09.2017 | A biotech company focused on inherited diseases just raised $135 million from a bunch of Wall Street firms | Courtsey BridgeBio
BridgeBio CEO Neil Kumar
A biotech focused on developing drugs to treat genetic diseases just raised $135 million.
Advertisement
BridgeBio Pharma, which was founded in 2015, builds out subsidiary companies around differen... |
| 19.05.2017 | Xontogeny Launches with $25M Series A Financing | Xontogeny, LLC, a Boston, MA-based new life sciences accelerator operating company focused on the early development of pharmaceuticals and other technologies, closed a $15m tranche of a $25m Series A financing.
Perceptive Advisors was the e... |
| 25.10.2016 | Perceptive Advisors Raises $323 Million Credit Opportunities Fund | Perceptive Advisors LLC, an investment management firm focused on the healthcare sector, today announced the closing of a new fund, the Perceptive Credit Opportunities Fund, that provides private credit to healthcare companies. The Fund and... |
| 23.08.2016 | Romulus Capital Leads $14M Series C for Vyome Biosciences | Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced today that it has closed a $14 million Series C financing round. This fina... |
| 23.08.2016 | Perceptive Advisors Leads $14M Series C for Vyome Biosciences | Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced today that it has closed a $14 million Series C financing round. This fina... |
| 22.08.2016 | Vyome Biosciences gets $14 mn from Perceptive Advisors, others | Delhi-based biopharmaceutical firm Vyome Biosciences Pvt. Ltd said on Monday it has received $14 million (Rs 94 crore) in a Series C funding round led by New York-based life sciences fund Perceptive Advisors and Boston-based venture capital... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.
Here are the 23 companie... |
| - | Investors disagree on whether digital health is in a bubble after another record funding haul in 2021 | If there were any doubts that digital health funding, especially in the U.S., is on a rocket ride straight to the stratosphere, they were removed with the latest funding report from CBInsights. Are we in a bubble? Is there irrational exuber... |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing |
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo... |